CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

2019-nCoV IgG/IgM Rapid Test CassetteWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (0)

Name (Synonyms) Correlation

Correlated MeSH Terms (9)

Name (Synonyms) Correlation
D054058 Acute Coronary Syndrome NIH 0.58
D054556 Venous Thromboembolism NIH 0.38
D009205 Myocarditis NIH 0.38
D009203 Myocardial Ischemia NIH 0.35
D020246 Venous Thrombosis NIH 0.32
D011655 Pulmonary Embolism NIH 0.32
D004617 Embolism NIH 0.30
D013923 Thromboembolism NIH 0.27
D013927 Thrombosis NIH 0.23

Correlated HPO Terms (5)

Name (Synonyms) Correlation
HP:0012819 Myocarditis HPO 0.38
HP:0001658 Myocardial infarction HPO 0.35
HP:0002625 Deep venous thrombosis HPO 0.32
HP:0002204 Pulmonary embolism HPO 0.32
HP:0001907 Thromboembolism HPO 0.24

There is one clinical trial.

Clinical Trials

1 Clinical Validation of a Simple and Fast Immunochromatographic Assay for Qualitative Determination of Specific ImmunoGLObulin IgG/IgM Antibodies to 2019- nCoV in Whole bLood, Serum or Plasma Specimen

In COVID-19 pandemic, it is of critical importance to identify a rapid and simple diagnostic method to be used in clinical settings to timely inform and refine strategies that can prevent, control, and stop the spread of SARS-CoV-2. The 2019-nCoV IgG/IgM Rapid Test Cassette (Whole Blood/Serum/Plasma) is a qualitative, membrane-based immunoassay for the detection of immunoglobulin G (IgG) and Immunoglobulin M (IgM) antibodies to SARS-CoV-2 in whole blood, serum or plasma specimen. Clinical specimens from patients who were suspected of being infected with 2019-nCoV will be used to evaluate the performance of the assay.

NCT04434417 COVID Device: 2019-nCoV IgG/IgM Rapid Test Cassette

Primary Outcomes

Description: Patients positive are serially tested with SARSCoV-2 lgM / IgG Rapid Test to evaluate the immune response in IgG negative patients and the reliability of the test in those patients who develop clinical signs of SARS-CoV-2 during the trial.

Measure: Evaluation of the rate of SARS-CoV-2 positive cancer patients and health professionals in a comprehensive cancer center or in a cancer setting.

Time: 6 months

Description: The 2019-nCoV IgG/IgM Rapid Test Cassette (Whole Blood/Serum/Plasma) was compared with a leading commercial Polymerase Chain Reaction

Measure: Evaluation of test accuracy

Time: 3 months

Description: Multiplex immunoassay

Measure: Interleukin-6 quantification

Time: 3 months

Description: Multiplex immunoassay

Measure: Interleukin-2 quantification

Time: 3 months

Description: Multiplex immunoassay

Measure: Interleukin-1 quantification

Time: 6 months

Description: Multiplex immunoassay

Measure: Tumor Necrosis Factor (TNF) quantification

Time: 3 months

Description: Multiplex immunoassay

Measure: Interferon gamma quantification

Time: 3 months

No related HPO nodes (Using clinical trials)